IAP拮抗剂揭示基于免疫反应的T细胞淋巴瘤新治疗策略
Tolinapant(ASTX660)是cIAP1/2和XIAP的强效非肽模拟拮抗剂,正在T细胞淋巴瘤患者中开展2期研究。研究整合体外、体内模型及人体肿瘤活检数据,发现tolinapant作为免疫调节分子,在完整免疫系统存在时诱导同基因TCL模型完全肿瘤消退。临床样本显示其可诱导与免疫调节一致的基因表达和细胞因子谱变化。
要点
- Tolinapant单药在复发/难治性外周TCL和皮肤TCL中显示临床活性。
- Tolinapant通过诱导免疫原性细胞死亡激活适应性和固有免疫。
- 完整免疫系统是同基因TCL模型中肿瘤完全消退的必要条件。
核心结论
- IAP拮抗剂tolinapant作为免疫调节分子,可促进TCL中强效抗肿瘤免疫反应。
研究设计与样本
- 整合体外和体内TCL模型,并经人体肿瘤活检数据验证的转化研究。
- Tolinapant正在T细胞淋巴瘤患者中开展2期研究。
主要发现
- Tolinapant在完整免疫系统存在的同基因TCL模型中诱导完全肿瘤消退。
- 临床样本显示tolinapant治疗可诱导与免疫调节一致的基因表达和细胞因子谱变化。
- Tolinapant通过诱导免疫原性细胞死亡激活适应性和固有免疫。
临床怎么用
- Tolinapant单药在复发/难治性外周TCL和皮肤TCL中显示临床活性证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tolinapant (ASTX660) is a potent, nonpeptidomimetic antagonist of cellular inhibitor of apoptosis proteins 1 and 2 (cIAP1/2) and X-linked IAP, which is currently being evaluated in a phase 2 study in T-cell lymphoma (TCL) patients. Tolinapant has demonstrated evidence of single-agent clinical activity in relapsed/refractory peripheral TCL and cutaneous TCL. To investigate the mechanism of action underlying the single-agent activity observed in the clinic, we have used a comprehensive translational approach integrating in vitro and in vivo models of TCL confirmed by data from human tumor biopsies. Here, we show that tolinapant acts as an efficacious immunomodulatory molecule capable of inducing complete tumor regression in a syngeneic model of TCL exclusively in the presence of an intact immune system. These findings were confirmed in samples from our ongoing clinical study showing that tolinapant treatment can induce changes in gene expression and cytokine profile consistent with immune modulation. Mechanistically, we show that tolinapant can activate both the adaptive and the innate arms of the immune system through the induction of immunogenic forms of cell death. In summary, we describe a novel role for IAP antagonists as immunomodulatory molecules capable of promoting a robust antitumor immune response in TCL.
引用
- Ferrari N, Ward G, Gewinner C, et al. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Adv. 2021. PMID: 34474469. doi:10.1182/bloodadvances.2020003955
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。